Roivant Sciences Ltd (ROIV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $28.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Roivant Sciences Ltd (ROIV) Stock Forecast
Analysts expect Roivant Sciences (ROIV) to earn -$1.47 per share in the fiscal year ending Mar 31, 2027, on revenue of $150.46M. Of 13 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 85% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 15.4% |
| Buy | 9 | 69.2% |
| Hold | 2 | 15.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 235.6%.
- Fiscal year ending Mar 31, 2027
- -$1.47
- EPS consensus, revenue $150.46M
- Fiscal year ending Mar 31, 2028
- -$1.61
- EPS consensus, revenue $504.93M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | -$1.47 | -$1.89 to -$1.23 | 3 | $150.46M | $114.96M to $171.62M | 3 |
| Mar 31, 2028 | -$1.61 | -$1.93 to -$1.27 | 3 | $504.93M | $119.00M to $953.00M | 12 |
Quarterly Estimates
The EPS consensus rises from -$0.41 for the quarter ending Dec 31, 2026 to -$0.30 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.50 to -$0.35 | 3 | $49.47M | $37.93M to $63.49M | 3 |
| Mar 31, 2027 | -$0.30 | -$0.46 to -$0.10 | 13 | $57.25M | $6.60M to $101.85M | 13 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 0 | 3 |
| Fiscal year ending Mar 31, 2028 | 1 | 0 |
| Quarter ending Dec 31, 2026 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has improved from -$1.58.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$1.47 | -$1.56 | -$1.58 | -$1.58 | -$1.58 | N/A |
| Fiscal year ending Mar 31, 2028 | -$1.61 | -$1.39 | -$1.72 | -$1.72 | -$1.72 | N/A |
| Quarter ending Dec 31, 2026 | -$0.41 | -$0.40 | -$0.41 | -$0.41 | -$0.41 | N/A |
Frequently Asked Questions About ROIV
What is the ROIV stock forecast?
Consensus analyst estimates put Roivant Sciences's EPS at -$1.47 for the fiscal year ending Mar 31, 2027, on revenue of $150.46M. The consensus rating from 13 analysts is Buy.
How do analysts rate ROIV stock?
Of 13 analysts covering Roivant Sciences, 2 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ROIV next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$1.47, with estimates from -$1.89 to -$1.23 from 3 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$1.61, with estimates from -$1.93 to -$1.27 from 3 analysts.
What revenue do analysts expect from Roivant Sciences next year?
For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $150.46M, with estimates from $114.96M to $171.62M. For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $504.93M, with estimates from $119.00M to $953.00M.
How many analysts cover ROIV?
13 analysts rate Roivant Sciences stock, and 3 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.
ROIV pages: Overview, Earnings, Forecast, Financials, Competitors